Chazova I.Ye. The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve). Systemic Hypertension. 2014;11(3):5-6. (In Russ.)
Email this article (Login required)
Email the author (Login required) OOO InterMedservice
Address: 121069, Russia, Moscow, Stolovy Lane, 6
Tel.: +7 (985) 763-98-00
e-mail: og@intermed.services
The media outlet is registered with the Federal Service for Supervision of Communications, Information Technology, and Mass Media (Roskomnadzor). Registration number and date of the decision on media registration: series EL No. FS 77 - 83918 dated 12.09.2022.
16+
Processing of personal data
